Australia's Imagion Biosystems soars on breast cancer detection device study

Imagion Biosystems

17/03/2022 03:45

** Shares of medical device maker Imagion Biosystems Ltd
 IBX.AX  surge as much as 65.1% to A$0.071, set for best session
since July 18, 2019 if gains hold
    ** Co says its MagSense HER2 product, which aims to detect
early breast cancer, was found to be safe and well-tolerated,
according to interim data  urn:newsml:reuters.com:*:nGLF115qhh
    ** "We have observed that the imaging agent, as
administered, is capable of reaching the lymph nodes" - Dr. Jane
Fox, the study's principal investigator
    ** Shares hit highest level since Feb. 11 
    ** About 60.5 mln shares change hands, nearly 20 times the
30-day average 
    ** IBX stock has lost 43.4% YTD, as of last close 

 (Reporting by Harshita Swaminathan)
 ((Harshita.Swaminathan@thomsonreuters.com))